



CLAIMS

1. A process for preparing an oligomeric compound of Formula (A):




- 5 wherein n is an integer from 10 to 40, and each R² is, independently for each occurrence, selected from the group consisting of:




wherein the process comprises the sequential steps of:

- 10 (a) contacting a compound of Formula (A1):



wherein R¹ is a support-medium and R³ is selected from the group consisting of trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl;


- 15 with a deblocking agent to form the compound of Formula (II):



(II);

wherein R^1 is a support-medium;


(b) contacting the compound of Formula (II) with a compound of Formula (A2):



(A2);

wherein R^3 is selected from the group consisting of trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl;


to form a compound of Formula (A3):



(A3);

wherein R^1 is a support-medium, and R^3 is selected from the group consisting of trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl;


(c) contacting the compound of Formula (A3) with a deblocking agent to form a compound of Formula (IV):



(IV);


wherein R¹ is a support-medium;

(d) contacting the compound of Formula (IV) with a compound of Formula (A4):




(A4);

wherein R³ is selected from the group consisting of trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl, and R⁴ is selected from the group consisting of:




(PC),

(DPG),



to form a compound of Formula (A5):




5


(A5);

wherein R^1 is a support-medium, R^3 is selected from the group consisting of trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl, and

R^4 is selected from:





- 5 (e) performing n-1 iterations of the sequential steps of:
- (e1) contacting the product formed by the immediately prior step with a deblocking agent; and
- (e2) contacting the compound formed by the immediately prior step with a compound of Formula (A8):



(A8);


wherein R³ is selected from the group consisting of trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl, and R⁴ is, independently for each compound of Formula (A8), selected from the group consisting of:







(A9);

wherein n is an integer from 10 to 40, R^1 is a support-medium, R^3 is selected from the group consisting of trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl, and R^4 is, independently for each occurrence, selected from the group consisting of:






(f) contacting the compound of Formula (A9) with a deblocking agent to form a compound of Formula (A10):




5

(A10);

wherein n is an integer from 10 to 40, R¹ is a support-medium, and R⁴ is, independently for each occurrence, selected from the group consisting of:




(g) contacting the compound of Formula (A10) with a cleaving agent to form a compound of
5 Formula (A11):




(A11);

wherein n is an integer from 10 to 40, and R^4 is, independently for each occurrence, selected from the group consisting of:




5



(j) contacting the compound of Formula (A11) with a deprotecting agent to form the oligomeric compound of Formula (A).

5


2. The process of claim 1, wherein the compound of Formula (A4) is of Formula (A4a):




wherein:


10 R³ is selected from the group consisting of trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl, and

R⁴ is selected from:







3. The process of claim 1 or 2, wherein the compound of Formula (A5) is of Formula
 5 (A5a):



- wherein:
 R¹ is a support-medium
 10 R³ is selected from the group consisting of trityl, monomethoxytrityl, dimethoxytrityl
 and trimethoxytrityl, and
 R⁴ is selected from:




- 5 4. The process of any one of claims 1-3, wherein the compound of Formula (A8) is of Formula (A8a):




wherein:

- 10 R³ is selected from the group consisting of trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl, and
- R⁴ is, independently at each occurrence of the compound of Formula (A8a), selected from the group consisting of:



5. The process of any one of claims 1-4, wherein the compound of formula (A9) is of Formula (A9a):



(A9a);


wherein:


n is an integer from 10 to 40,

5 R^1 is a support-medium


R^3 is selected from the group consisting of trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl, and

R^4 is, independently for each occurrence, selected from the group consisting of:





6. The process of any one of claims 1-5, wherein the compound of Formula (A10) is of
 5 Formula (A10a):




(A10a);

wherein:


n is an integer from 10 to 40,

10 R¹ is a support-medium, and

R⁴ is, independently for each occurrence, selected from the group consisting of:




- 5 7. The process of any one of claims 1-6, wherein the compound of Formula (A11) is of Formula (A11a):




(A11a);

wherein:

n is an integer from 10 to 40, and


5 R^4 is, independently for each occurrence, selected from the group consisting of:



- 5 8. The process of any one of claims 1-7, wherein for the oligomeric compound of Formula (A), n is 30, and R² is at each position from 1 to 30 and 5' to 3':


Position No. 5' to 3'	R ²	Position No. 5' to 3'	R ²	Position No. 5' to 3'	R ²
1	C	11	A	21	G
2	T	12	A	22	C
3	C	13	G	23	A
4	C	14	G	24	T
5	A	15	A	25	T
6	A	16	A	26	T
7	C	17	G	27	C
8	A	18	A	28	T
9	T	19	T	29	A
10	C	20	G	30	G

wherein the oligomeric compound of Formula (A) is a compound of Formula (E):



or a pharmaceutically acceptable salt thereof.

- 5 9. The process of claim 8, wherein the oligomeric compound of Formula (E) is an oligomeric compound of Formula (XII):




(XII),

or a pharmaceutically acceptable salt thereof.


5

10. The process of claim 1, for preparing an oligomeric compound of Formula (E):




wherein the process comprises the sequential steps of:

(a) contacting a compound of Formula (I):



wherein R^1 is a support-medium,


with a deblocking agent to form the compound of Formula (II):



(II);

wherein R¹ is a support-medium;


(b) contacting the compound of Formula (II) with compound (B):



5

(B);


to form a compound of Formula (III):



(III);

10 wherein R¹ is a support-medium;


(c) contacting the compound of Formula (III) with a deblocking agent to form a compound of Formula (IV):



(IV);


wherein R^1 is a support-medium;

(d) contacting the compound of Formula (IV) with a compound of Formula (C):




(C);

to form a compound of Formula (V):




wherein R^1 is a support-medium;

- (e) contacting the compound of Formula (V) with a deblocking agent to form a compound of
- 5 Formula (VI):




wherein R^1 is a support-medium;

- 10 (f) contacting the compound of Formula (VI) with compound of Formula (F):



(F);

to form a compound of Formula (VII):



(VII);


5

wherein R¹ is a support-medium;

(g) performing 28 iterations of the sequential steps of:


(g1) contacting the product formed by the immediately prior step with a deblocking agent; and

(g2) contacting the compound formed by the immediately prior step with a compound of Formula (VIII):



(VIII);

- 5 wherein R^2 is, independently for each compound of Formula (VIII), selected from the group consisting of:




10 wherein, for each iteration from 1 to 28, R^2 is:

Iteration No.	R^2	Iteration No.	R^2	Iteration No.	R^2
1	PC	11	DPG	21	PA
2	PC	12	DPG	22	T
3	PA	13	PA	23	T
4	PA	14	PA	24	T
5	PC	15	DPG	25	PC


6	PA	16	PA	26	T
7	T	17	T	27	PA
8	PC	18	DPG	28	DPG
9	PA	19	DPG		
10	PA	20	PC		

to form a compound of Formula (IX):



(IX);


- 5 wherein R¹ is a support-medium,
 wherein R² is, independently for each occurrence, selected from the group consisting
 of:



wherein R^2 is at each position from 1 to 30 and 5' to 3':

Position No. 5' to 3'	R^2	Position No. 5' to 3'	R^2	Position No. 5' to 3'	R^2
1	PC	11	PA	21	DPG
2	T	12	PA	22	PC
3	PC	13	DPG	23	PA
4	PC	14	DPG	24	T
5	PA	15	PA	25	T
6	PA	16	PA	26	T
7	PC	17	DPG	27	PC
8	PA	18	PA	28	T
9	T	19	T	29	PA
10	PC	20	DPG	30	DPG


- 5 (h) contacting the compound of Formula (IX) with a deblocking agent to form a compound of Formula (X):



(X);

wherein R^1 is a support-medium,wherein R^2 is, independently for each occurrence, selected from the group consisting


5 of:

wherein R^2 is at each position from 1 to 30 and 5' to 3':

Position No. 5' to 3'	Position No. 5' to 3'	Position No. 5' to 3'
R^2	R^2	R^2

1	PC	11	PA	21	DPG
2	T	12	PA	22	PC
3	PC	13	DPG	23	PA
4	PC	14	DPG	24	T
5	PA	15	PA	25	T
6	PA	16	PA	26	T
7	PC	17	DPG	27	PC
8	PA	18	PA	28	T
9	T	19	T	29	PA
10	PC	20	DPG	30	DPG


(i) contacting the compound of Formula (X) with a cleaving agent to form a compound of Formula (XI):



5

(XI),

wherein R^2 is, independently for each occurrence, selected from the group consisting of:



wherein R^2 is at each position from 1 to 30 and 5' to 3':

Position No. 5' to 3'	R^2	Position No. 5' to 3'	R^2	Position No. 5' to 3'	R^2
1	PC	11	PA	21	DPG
2	T	12	PA	22	PC
3	PC	13	DPG	23	PA
4	PC	14	DPG	24	T
5	PA	15	PA	25	T
6	PA	16	PA	26	T
7	PC	17	DPG	27	PC
8	PA	18	PA	28	T
9	T	19	T	29	PA
10	PC	20	DPG	30	DPG

and

- 5 (j) contacting the compound of Formula (XI) with a deprotecting agent to form the oligomeric compound of Formula (E).

11. The process of any one of claims 1-10, wherein step (d) or step (e2) further comprises contacting the compound of Formula (IV) or the compound formed by the immediately prior step, respectively, with a capping agent.

5 12. The process of any one of claims 1-11, wherein the deblocking agent used in each step is halogenated acid or cyanoacetic acid.


13. The process of claim 12, wherein the halogenated acid is selected from the group consisting of chloroacetic acid, dichloroacetic acid, trichloroacetic acid, fluoro acetic acid,
10 difluoroacetic acid, and trifluoroacetic acid.

14. The process of any one of claims 1-13, wherein at least one of steps (a), (c), (e1), and (f) further comprise the step of contacting the deblocked compound of each step with a neutralization agent.

15

15. The process of any one of claims 1-14, wherein the support-medium comprises a material selected from the group consisting of glass, modified or functionalized glass, plastics (including acrylics, polystyrene (e.g., polystyrene with 1% crosslinked divinylbenzene), copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene,
20 polyurethanes, and TEFLON), polysaccharides, nylon or nitrocellulose, ceramics, resins, silica or silica-based materials (including silicon and modified silicon), carbon, metals, and optical fiber bundles.


16. A compound selected from the group consisting of Formula (A1):



25

(A1),

and Formula (A3):




(A3)

or a pharmaceutically acceptable salt thereof, wherein:

each R^1 is independently a support-medium; and

5 each R³ is independently selected from the group consisting of hydrogen, trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl.

17. A compound of Formula (A5):




(A5)

or a pharmaceutically acceptable salt thereof, wherein:


R^1 is a support-medium;

R³ is selected from the group consisting of hydrogen, trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl; and

15 R^4 is, independently at each occurrence, selected from the group consisting of:



- 5 18. The compound of claim 17, wherein the compound of Formula (A5) is of Formula (A5a):





(A5a);

wherein:

 R^1 is a support-medium

- 5 R^3 is selected from the group consisting of trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl, and


 R^4 is selected from:



19. The compound of claim 18, wherein R^3 is trityl.

5

20. A compound of Formula (A9):




(A9),

or a pharmaceutically acceptable salt thereof, wherein:


- 10 n is an integer from 10 to 40;
 R^1 is a support-medium;

R^3 is selected from the group consisting of hydrogen, trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl; and

R^4 is, independently at each occurrence, selected from the group consisting of:



21. The compound of claim 20, wherein the compound Formula (A9) is of Formula (A9a):



(A9a);


wherein:


n is an integer from 10 to 40,

5 R^1 is a support-medium


R^3 is selected from the group consisting of trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl, and

R^4 is, independently for each occurrence, selected from the group consisting of:





22. The compound of claim 20, wherein the compound Formula (A9) is of Formula (IX):




5

(IX),

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is a support-medium, and

R^2 is, independently at each occurrence, selected from the group consisting of:




wherein R^2 is at each position from 1 to 30 and 5' to 3':

Position No. 5' to 3'	R^2	Position No. 5' to 3'	R^2	Position No. 5' to 3'	R^2
1	PC	11	PA	21	DPG
2	T	12	PA	22	PC
3	PC	13	DPG	23	PA
4	PC	14	DPG	24	T
5	PA	15	PA	25	T
6	PA	16	PA	26	T
7	PC	17	DPG	27	PC
8	PA	18	PA	28	T
9	T	19	T	29	PA
10	PC	20	DPG	30	DPG

5

23. The compound of claim 22, wherein the compound of Formula (IX) is of Formula (IXa):





(IXa),

or a pharmaceutically acceptable salt thereof, wherein


5 R^1 is a support-medium, and

R^2 is, independently at each occurrence, selected from the group consisting of:





(T), and




(PA), and

wherein R^2 is at each position from 1 to 30 and 5' to 3':

Position No. 5' to 3'	R^2	Position No. 5' to 3'	R^2	Position No. 5' to 3'	R^2
1	PC	11	PA	21	DPG
2	T	12	PA	22	PC
3	PC	13	DPG	23	PA
4	PC	14	DPG	24	T
5	PA	15	PA	25	T
6	PA	16	PA	26	T
7	PC	17	DPG	27	PC
8	PA	18	PA	28	T
9	T	19	T	29	PA
10	PC	20	DPG	30	DPG

- 5 24. The compound of claim 20, wherein the compound of Formula (A9) is of Formula (Xa):




(Xa),

or a pharmaceutically acceptable salt thereof, wherein

 R^1 is a support-medium, and

5 R^2 is, independently at each occurrence, selected from the group consisting of:

wherein R^2 is at each position from 1 to 30 and 5' to 3':


Position No. 5' to 3' R^2 | Position No. 5' to 3' R^2 | Position No. 5' to 3' R^2

1	PC	11	PA	21	DPG
2	T	12	PA	22	PC
3	PC	13	DPG	23	PA
4	PC	14	DPG	24	T
5	PA	15	PA	25	T
6	PA	16	PA	26	T
7	PC	17	DPG	27	PC
8	PA	18	PA	28	T
9	T	19	T	29	PA
10	PC	20	DPG	30	DPG

25. The compound of any one of claims 16-24, wherein the support-medium comprises polystyrene.

5

26. A compound of Formula (A11):



(A11),


or a pharmaceutically acceptable salt thereof, wherein:

10 n is an integer from 10 to 40;


R^1 is a support-medium;

R^3 is selected from the group consisting of trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl; and

R^4 is, independently at each occurrence, selected from the group consisting of:




27. The compound of claim 26, wherein the compound of Formula (A11) is of formula (A11a):
- 10




(A11a),


or a pharmaceutically acceptable salt thereof, wherein:

n is an integer from 10 to 40;

5 R^1 is a support-medium; R^3 is selected from the group consisting of trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl; and R^4 is, independently at each occurrence, selected from the group consisting of:




28. The compound of claim 26, wherein the compound Formula (A11) is of Formula
 5 (XI):



(XI),

or a pharmaceutically acceptable salt thereof, wherein:

R^2 is, independently at each occurrence, selected from the group consisting of:




wherein R^2 is at each position from 1 to 30 and 5' to 3':

Position No. 5' to 3'	R^2	Position No. 5' to 3'	R^2	Position No. 5' to 3'	R^2
1	PC	11	PA	21	DPG
2	T	12	PA	22	PC
3	PC	13	DPG	23	PA
4	PC	14	DPG	24	T
5	PA	15	PA	25	T
6	PA	16	PA	26	T
7	PC	17	DPG	27	PC
8	PA	18	PA	28	T
9	T	19	T	29	PA
10	PC	20	DPG	30	DPG


5

29. The compound of claim 28, wherein the compound of Formula (XI) is of Formula (XIa):



(XIa),

or a pharmaceutically acceptable salt thereof, wherein

 R^2 is, independently at each occurrence, selected from the group consisting of:wherein R^2 is at each position from 1 to 30 and 5' to 3':

Position No. 5' to 3'	R ²	Position No. 5' to 3'	R ²	Position No. 5' to 3'	R ²
1	PC	11	PA	21	DPG
2	T	12	PA	22	PC
3	PC	13	DPG	23	PA
4	PC	14	DPG	24	T
5	PA	15	PA	25	T
6	PA	16	PA	26	T
7	PC	17	DPG	27	PC
8	PA	18	PA	28	T
9	T	19	T	29	PA
10	PC	20	DPG	30	DPG